NYSEAMERICAN:VNRX - VolitionRX Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding VolitionRX Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $4.57 -0.41 (-8.23 %) (As of 02/23/2020 02:54 PM ET) Add Compare Today's Range$4.56Now: $4.57▼$5.1950-Day Range N/A52-Week Range$2.65Now: $4.57▼$6.84Volume305,376 shsAverage Volume86,014 shsMarket Capitalization$188.31 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. The company develops blood-based Nu.Q immunoassays to detect specific biomarkers. VolitionRX Limited is based in Singapore. Industry, Sector and Symbol Stock Exchange NYSEAMERICAN Industry Medical Laboratories & Research Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:VNRX Previous SymbolNYSEMKT:VNRX CUSIPN/A CIKN/A Webhttp://www.volitionrx.com/ Phone646 650 1351Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees44 Outstanding Shares41,205,000Market Cap$188.31 million Next Earnings Date5/13/2020 (Estimated) OptionableNot Optionable Receive VNRX News and Ratings via Email Sign-up to receive the latest news and ratings for VNRX and its competitors with MarketBeat's FREE daily newsletter. AMEX:VNRX Rates by TradingView VolitionRX (NYSEAMERICAN:VNRX) Frequently Asked Questions What is VolitionRX's stock symbol? VolitionRX trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "VNRX." How were VolitionRX's earnings last quarter? VolitionRX Ltd (NYSEAMERICAN:VNRX) released its earnings results on Tuesday, November, 12th. The medical research company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.01. The medical research company earned $0.02 million during the quarter, compared to analyst estimates of $0.06 million. View VolitionRX's Earnings History. When is VolitionRX's next earnings date? VolitionRX is scheduled to release their next quarterly earnings announcement on Wednesday, May 13th 2020. View Earnings Estimates for VolitionRX. What price target have analysts set for VNRX? 2 brokers have issued 12 month price objectives for VolitionRX's shares. Their forecasts range from $5.00 to $8.00. On average, they anticipate VolitionRX's share price to reach $6.50 in the next year. This suggests a possible upside of 42.2% from the stock's current price. View Analyst Price Targets for VolitionRX. What is the consensus analysts' recommendation for VolitionRX? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VolitionRX in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for VolitionRX. Has VolitionRX been receiving favorable news coverage? News coverage about VNRX stock has trended negative recently, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. VolitionRX earned a coverage optimism score of -2.4 on InfoTrie's scale. They also assigned headlines about the medical research company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for VolitionRX. Are investors shorting VolitionRX? VolitionRX saw a increase in short interest in January. As of January 15th, there was short interest totalling 625,000 shares, an increase of 22.4% from the December 31st total of 510,800 shares. Based on an average daily trading volume, of 124,300 shares, the days-to-cover ratio is presently 5.0 days. Currently, 2.6% of the company's shares are short sold. View VolitionRX's Current Options Chain. Who are some of VolitionRX's key competitors? Some companies that are related to VolitionRX include Spectral Medical (EDT), ANGLE (AGL), Proteome Sciences (PRM), DiaSorin (DIA), Polarityte (COOL) and Premaitha Health (NIPT). What other stocks do shareholders of VolitionRX own? Based on aggregate information from My MarketBeat watchlists, some companies that other VolitionRX investors own include Chesapeake Energy (CHK), Bausch Health Companies (BHC), Verastem (VSTM), Bausch Health Companies (BHC), Exelixis (EXEL), ContraFect (CFRX), Gilead Sciences (GILD), Verizon Communications (VZ), NovaBay Pharmaceuticals (NBY) and Crispr Therapeutics (CRSP). Who are VolitionRX's key executives? VolitionRX's management team includes the folowing people: Dr. Martin Charles Faulkes, Exec. Chairman (Age 75)Mr. Cameron Reynolds, Founder, CEO, Pres & Director (Age 48)Dr. Jacob Vincent Micallef Ph.D., MBA, Chief Scientific Officer (Age 63)Dr. Jason Bradley Terrell, Chief Medical Officer (Age 39)Mr. Rodney Gerard Rootsaert LLB, Corp. Sec. (Age 48) Who are VolitionRX's major shareholders? VolitionRX's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Geode Capital Management LLC (0.50%), Renaissance Technologies LLC (0.13%), California Public Employees Retirement System (0.05%), Advisor Group Inc. (0.05%), Oxford Asset Management LLP (0.03%) and State Street Corp (0.03%). Company insiders that own VolitionRX stock include Cameron John Reynolds, Corp Ltd Eight, Guy Archibald Innes and Martin Charles Faulkes. View Institutional Ownership Trends for VolitionRX. Which major investors are selling VolitionRX stock? VNRX stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC and Geode Capital Management LLC. View Insider Buying and Selling for VolitionRX. Which major investors are buying VolitionRX stock? VNRX stock was bought by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, Oxford Asset Management LLP, State Street Corp and Advisor Group Inc.. Company insiders that have bought VolitionRX stock in the last two years include Cameron John Reynolds, Corp Ltd Eight, Guy Archibald Innes and Martin Charles Faulkes. View Insider Buying and Selling for VolitionRX. How do I buy shares of VolitionRX? Shares of VNRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is VolitionRX's stock price today? One share of VNRX stock can currently be purchased for approximately $4.57. How big of a company is VolitionRX? VolitionRX has a market capitalization of $188.31 million. VolitionRX employs 44 workers across the globe.View Additional Information About VolitionRX. What is VolitionRX's official website? The official website for VolitionRX is http://www.volitionrx.com/. How can I contact VolitionRX? The medical research company can be reached via phone at 646 650 1351. MarketBeat Community Rating for VolitionRX (NYSEAMERICAN VNRX)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 177 (Vote Outperform)Underperform Votes: 160 (Vote Underperform)Total Votes: 337MarketBeat's community ratings are surveys of what our community members think about VolitionRX and other stocks. Vote "Outperform" if you believe VNRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VNRX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/23/2020 by MarketBeat.com StaffFeatured Article: Does a trade war provide a risk to the global economy?
